Elutia Yönetim
Yönetim kriter kontrolleri 3/4
Elutia CEO'su Randy Mills, Jun2022 tarihinde atandı, in görev süresi 3.92 yıldır. in toplam yıllık tazminatı $ 1.34M olup, şirket hissesi ve opsiyonları dahil olmak üzere 44.6% maaş ve 55.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.93% ine doğrudan sahiptir ve bu hisseler $ 474.91K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 5.7 yıldır.
Anahtar bilgiler
Randy Mills
İcra Kurulu Başkanı
US$1.3m
Toplam tazminat
| CEO maaş yüzdesi | 44.63% |
| CEO görev süresi | 3.9yrs |
| CEO sahipliği | 0.9% |
| Yönetim ortalama görev süresi | 3.8yrs |
| Yönetim Kurulu ortalama görev süresi | 5.7yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Mar 04
ELUT: Listing Compliance Recovery Will Support Future Reconstructive Portfolio Upside
Analysts have adjusted their price target on Elutia to reflect updated views on profitability, with a lower assumed profit margin and a higher future P/E estimate shaping the new valuation in dollar terms. What's in the News Elutia received a written notice from Nasdaq on December 23, 2025 stating that it is not in compliance with the minimum market value of listed securities requirement of $35 million under Nasdaq Listing Rule 5550(b)(2) (Key Developments).Anlatı Güncellemesi • Feb 18
ELUT: Listing Compliance Progress Will Support Future Reconstructive Portfolio Upside
Analysts have revised their price target on Elutia to $3.50, maintaining their fair value estimate while updating assumptions on the discount rate, revenue growth, profit margin, and future P/E to align with their current assessment of the company’s risk and earnings profile. What's in the News Elutia received a written notice from Nasdaq stating that it is not in compliance with the minimum market value of listed securities requirement of $35m under Listing Rule 5550(b)(2).Analiz Makalesi • Feb 15
Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
Anlatı Güncellemesi • Feb 04
ELUT: Future Nasdaq Compliance Resolution Will Support Bullish Repricing Potential
Analysts have maintained their price target on Elutia at US$5.00, citing a slightly lower discount rate, a modest change in expected revenue contraction, and a small adjustment to future P/E assumptions, along with a slightly higher projected profit margin. What's in the News On December 23, 2025, Elutia received a Nasdaq notice that its market value of listed securities had been below the US$35 million minimum for 30 consecutive business days, and that it also did not meet certain shareholder equity and net income standards required for continued listing on The Nasdaq Capital Market (Nasdaq notice).Anlatı Güncellemesi • Jan 21
ELUT: Future Nasdaq Compliance Progress Will Drive Bullish Repricing Potential
Narrative Update on Elutia Analysts have maintained their price target for Elutia at US$5.00, citing slightly lower assumed revenue growth, a modestly higher profit margin outlook, and a small adjustment to the discount rate and future P/E assumptions as key drivers behind the updated view. What's in the News On December 23, 2025, Nasdaq notified Elutia that its market value of listed securities had been below the US$35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive business days, and that the company also did not meet related shareholder equity or net income standards (Nasdaq notice).Anlatı Güncellemesi • Jan 07
ELUT: Future Compliance Recovery Will Support Bullish Repricing Potential
Analysts have reduced their price target on Elutia by US$1.00. They cite a higher discount rate, a projected revenue decline of 7.18%, and a much higher future P/E estimate, partly offset by slightly stronger expected profit margins.Anlatı Güncellemesi • Dec 16
ELUT: Future Listing Compliance Efforts Will Support Reconstructive Portfolio Expansion
Narrative Update on Elutia Analysts have modestly adjusted their price target on Elutia upward to reflect a slightly more constructive long term earnings and valuation outlook, nudging the fair value estimate higher by approximately $0.00 per share as updated model inputs had only a de minimis impact on the overall target. What's in the News Elutia received a notice from Nasdaq that its Class A common stock has traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a formal deficiency notification and potential delisting process (Nasdaq listing notice).Analiz Makalesi • Dec 06
Lacklustre Performance Is Driving Elutia Inc.'s (NASDAQ:ELUT) 28% Price Drop
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 28% in the last...Anlatı Güncellemesi • Dec 02
ELUT: Recent Business Sale Will Fund Breast Reconstruction Growth Ahead
Analysts have lowered Elutia's target price from $8.00 to $6.00, citing a smaller-than-expected sale price for the BioEnvelope business. However, they note that the deal removes significant overhangs and provides full funding for Elutia's breast reconstruction segment.Anlatı Güncellemesi • Nov 17
ELUT: Recent Business Sale Will Unlock Breast Reconstruction Focus
Narrative Update on Elutia Elutia's analyst price target has been reduced from $8 to $6 following analysts’ assessment that, although the sale of the BioEnvelope business provides significant funding, the lower-than-expected acquisition price tempers near-term expectations for the company's growth. Analyst Commentary Analysts have weighed in on the implications of Elutia's recent business developments, offering a nuanced perspective on the company's outlook.Anlatı Güncellemesi • Nov 01
ELUT: Breast Reconstruction Funding Will Drive Long-Term Shareholder Value
Elutia's analyst price target has decreased from $8 to $6, as analysts factor in the sale of its BioEnvelope business. While this sale is seen as bittersweet, it helps eliminate notable uncertainties and secures funding for the company's breast reconstruction segment.Anlatı Güncellemesi • Oct 17
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia from $8 to $6 per share, citing both the lower-than-expected sale price of its BioEnvelope business and the improved funding outlook for its core breast reconstruction segment. Analyst Commentary Recent analyst reports provide a nuanced view of Elutia's prospects following the BioEnvelope business sale.Analiz Makalesi • Oct 13
The Market Doesn't Like What It Sees From Elutia Inc.'s (NASDAQ:ELUT) Revenues Yet As Shares Tumble 30%
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 30% in the last...Anlatı Güncellemesi • Oct 03
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia, with recent adjustments citing a new range from $8 to $5 per share. This reflects cautious optimism about the firm's strategic divestiture and future growth prospects, despite near-term revenue challenges.Anlatı Güncellemesi • Sep 10
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50. What's in the News Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.Analiz Makalesi • Aug 29
Elutia Inc.'s (NASDAQ:ELUT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Elutia Inc. ( NASDAQ:ELUT ) shareholders have had their patience rewarded with a 27% share price jump in the last...Analiz Makalesi • Aug 19
US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results
NasdaqCM:ELUT 1 Year Share Price vs Fair Value Explore Elutia's Fair Values from the Community and select yours Elutia...Anlatı Güncellemesi • Aug 19
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50. What's in the News Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.Analiz Makalesi • Jun 18
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Elutia Inc. ( NASDAQ:ELUT ) may be sending very bullish signals at the...
Yeni Anlatı • Apr 06
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space.Analiz Makalesi • Jan 04
Elutia Inc. (NASDAQ:ELUT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Elutia Inc. ( NASDAQ:ELUT ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Analiz Makalesi • Nov 20
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%
Elutia Inc. ( NASDAQ:ELUT ) shareholders would be excited to see that the share price has had a great month, posting a...Analiz Makalesi • Jun 28
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone...Analiz Makalesi • Mar 10
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
One thing we could say about the analysts on Elutia Inc. ( NASDAQ:ELUT ) - they aren't optimistic, having just made a...Analiz Makalesi • Feb 21
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Elutia Inc. ( NASDAQ:ELUT ) is definitely a stock...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$22m |
| Dec 31 2025 | US$1m | US$600k | -US$16m |
| Sep 30 2025 | n/a | n/a | -US$25m |
| Jun 30 2025 | n/a | n/a | -US$22m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$5m | US$600k | -US$45m |
| Sep 30 2024 | n/a | n/a | -US$53m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$2m | US$600k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$35m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | US$2m | US$321k | -US$36m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$146k | n/a | -US$25m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$142k | n/a | -US$25m |
Tazminat ve Piyasa: Randy 'nin toplam tazminatı ($USD 1.34M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 626.93K ).
Tazminat ve Kazançlar: Randy 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Randy Mills (53 yo)
3.9yrs
Görev süresi
US$1,344,284
Tazminat
Dr. C. Randal Mills, Ph D., also known as Randy, has been Director of Elutia Inc. (formerly known as Aziyo Biologics, Inc.) since November 2015. Dr. Mills served as a Member of Advisory Board at eXpanded e...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 3.9yrs | US$1.34m | 0.93% $ 474.9k | |
| Chief Financial Officer | 5.7yrs | US$747.03k | 1.07% $ 547.6k | |
| Chief Scientific Officer | 3.8yrs | US$688.70k | 0.25% $ 127.4k | |
| Head of People | less than a year | Veri yok | Veri yok | |
| VP & Head of Emerging Businesses | 4.3yrs | Veri yok | Veri yok | |
| Head of Cardiovascular | 1yr | Veri yok | Veri yok | |
| Chief Commercial Officer | less than a year | Veri yok | Veri yok | |
| Senior VP of Finance | no data | Veri yok | Veri yok |
3.8yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: ELUT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 10.5yrs | US$1.34m | 0.93% $ 474.9k | |
| Independent Chairman & Lead Independent Director | 10.5yrs | US$321.50k | 1.17% $ 601.5k | |
| Independent Director | 5.7yrs | US$161.00k | 0.061% $ 31.3k | |
| Independent Director | less than a year | US$196.25k | 0.28% $ 145.0k | |
| Independent Director | 3.6yrs | US$138.50k | 0.070% $ 36.1k |
5.7yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ELUT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/26 07:27 |
| Gün Sonu Hisse Fiyatı | 2026/05/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Elutia Inc. 6 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |